Study Shows Circulating Tumor Cell Chips Track Cancer Drug Response
This article was originally published in The Gray Sheet
Executive Summary
Circulating tumor cell chips show promise as monitors of cancer therapy response in a study led by the Massachusetts General Hospital Cancer Center published July 2 in the New England Journal of Medicine
You may also be interested in...
J&J’s Veridex To Lead Development Of Next-Gen Cancer Diagnostic
Johnson & Johnson subsidiary Veridex will partner with Massachusetts General Hospital to help bring a next-generation cancer blood test to market, both institutions announced Jan. 3.
J&J’s Veridex To Lead Development Of Next-Gen Cancer Diagnostic
Johnson & Johnson subsidiary Veridex will partner with Massachusetts General Hospital to help bring a next-generation cancer blood test to market, both institutions announced Jan. 3.
Circulating Tumor Cell Dx Is Technology To Watch In 2009 – Cleveland Clinic
Use of circulating tumor cell assays to predict chemotherapy success will be the most significant medical innovation to break through in 2009, a panel of Cleveland Clinic physicians predicts